The impact of minimal residual disease in acute leukemia is well established in patient outcome.
In this webinar, Cytognos's guest speaker Evan Jensen, will review the evolution of clinical flow cytometry for the evaluation of minimal residual disease (MRD) in acute leukemia over the years. He will also describe the clinical relevance of MRD, current state-of-the-art methodology and the most important technical aspects to perform a good flow cytometry measurement.
Primary immunodeficiencies (PID) are hereditary disorders where cell types can be absent, decreased or dysfunctional. The majority of PID patients have a defect in the lymphoid system, involving B- and/or T-cells alone or in combination with other cells.
In this webinar, Tomas Kalina will explain the role of flow cytometry in the diagnostics of PID, how to perform severe combined immunodeficiency (SCID) screening by cytometry and what is the expected immunophenotypical changes in PID.
It is imperative that laboratories offer accurate and reliable results through well standardized technical processes by establishing rigorous operating procedures.
In this webinar, Elaine Sobral da Costa explains how to perform differential diagnosis of acute leukemia, evaluate ALL MRD and immunodeficiency, and how to design and validate new panels.
Learn about the emergence of benzimidazole opioids like Isotonitazene from Cayman scientist Nathan Layle. Listen as Nathan discusses when and where they appeared and why they are a threat. During the webinar, he also examines current trends surrounding new analogs and reviews the differences in the GC-MS spectra that occur when substitutions are made.
Explore more in Cayman's article Isotonitazene: The Latest Substance to Be Banned in the European Union.
Download the NPS Snapshot: Nitazenes guide.
Learn about the emergence of benzimidazole opioids like Isotonitazene from Cayman scientist Nathan Layle. Listen as Nathan discusses when and where they appeared and why they are a threat. During the webinar, he also examines current trends surrounding new analogs and reviews the differences in the GC-MS spectra that occur when substitutions are made. Explore […]
This webinar is hold by Vincent van der Velden (in Dutch) where he describes how flow cytometry plays a fundamental role in the diagnosis of acute leukemias because immunophenotyping to determine the cell line involved. By using databases, this diagnosis can be further standardized so that reliable and reproducible data can be generated.
The level of minimal residual disease (MRD) is paramount to link the depth of response and long-term outcome. Recent advances in treatment demand a more sensitive response criteria which includes MRD evaluation. Therefore, MRD has been defined as one of the best surrogate markers to predict overall survival and accelerate the approval of new therapies in Multiple Myeloma (MM).
In this webinar, Mantas Radzevičius explain the experience with MM MRD in his clinical laboratory, from a theoretical and practical perspective.
Acute leukemia is a heterogeneous group of disease reflecting stem cell of origin, capacity of maturation and commitment to a specific lineage. Leukemic cells may show early or minimal differentiation and some diagnostic entities can easily be confused with others because of their atypical immunophenotype.
Entities associated with a poor prognosis can be misdiagnosed as acute myeloid leukemia with minimal differentiation (AML-M0) if proper immunophenotyping panels are not routinely performed. In this webinar, Rafik Terra will explain how the use of the EuroFlow™ standardized approach has the potential to improve the diagnostic accuracy of rare entities like BPDCN and ETP-ALL.
The adaptive immune response to SARS-CoV-2 includes specific antibody and T cell responses. The identification of a subpopulation of specific CD4 effector T cells that present the activation markers CD134 (OX40) and CD25 on their surface, which can be detected and quantified by flow cytometry after incubating blood with mitogens and/or specific antigens of pathogens to study, has demonstrated its utility in other infections
In this webinar, Eduardo López Granados, MD, PhD and Luz Yadira Bravo Gallego, MD explain their preliminary experience as an Immunology laboratory in the setting-up of the OX40 assay for the identification of CD4+ T cell specific responses to SARS-CoV-2 peptides, together with its ongoing application to determine the extent and characteristics of the response to natural infection and vaccination.
In this workshop, Irene González Barahona (Key Account Manager from East Coast – US and Canada) presents Cytognos Next Generation Flow solution for MM MRD assays which allows for a highly sensitive and effective detection of abnormal plasma cells at very low levels, provides information about sample quality (hemodilution) and bone marrow regeneration after therapy.
This workshop was first displayed at ICCS 2020. Watch this video to learn how you can improve the care of patients with Multiple Myeloma by using this complete flow approach.
The EuroFlow™ Lymphoid Screening tube (LST) was designed to identify the major T and B-cell subsets, in addition to NK-cells, monocytes, neutrophils and eosinophils. In the context of hemato-oncology and multiparametric flow cytometry, the classical expert-guided manual gating strategies based on bi-variate dot plots to identify aberrant and residual normal cell populations has become suboptimal in routine diagnosis.
In this webinar, Maria Arroz will address an alternative approach based on automated gating and classification algorithms.
In this workshop, Irene González Barahona (Key Account Manager from East Coast – US and Canada) presents Infinicyt™ security features to ensure traceability and security of your patient data such as User Access Control, Password-protected Files, Audit Trails and Electronic Signatures.
This workshop was first displayed at ICCS 2020. Watch this video to learn how Infinicyt software can help you meeting regulatory compliance and standards requirements of your clinical laboratory (FDA 21 CFR Part 11 regulation & ISO 15189:2003).